Multicystic Dysplastic Kidney Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Multicystic Dysplastic Kidney. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Multicystic Dysplastic Kidney receives a directional score of 70/100, combining unmet need (86/100), competitive intensity (66/100) and market attractiveness (77/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A nongenetic defect due to malformation of the KIDNEY which appears as a bunch of grapes with multiple renal cysts but lacking the normal renal bean shape, and the collection drainage system. This condition can be detected in-utero with ULTRASONOGRAPHY.

The reproducible record is Patsnap disease ID 6e35dfbd760d47a18dc04c77068a88bf and MeSH identifier D021782. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: USRDS 2021 Annual Data Report - CKD Among Children and Adolescents

### Chart Data Transcription Report 1. Basic Chart Information * Chart Title: Figure 5.1 Kidney disorders by type in children with kidney disease, 2019 * Chart Type: Bar Chart * Contextual Summary: This bar chart illustrates the distribution of different kidney disorder types among children with kidney disease in 2019, specifically for the commercially insured cohort. 2. Chart Structure and Elements * Axes/Headers: * X-Axis: Types of Kidney Disorders (CAKUT, GN, Cystic, Diabetes-related, CKD NOS, Other) * Y-Axis: Percentage * Legend/Groups: Not applicable; categories are indicated on the X-axis. * Notes and Footnotes: Data source: Optum de-identified Clinformatics Data Mart database. December 31, 2019 point prevalent enrollees with kidney disease, aged 0-17 years. Abbreviations: CAKUT, congenital anomalies of the kidney and urinary tract; GN, glomerulonephritis; NOS, not otherwise specified. 3. Detailed Data Transcription This bar chart displays the percentage distribution of different kidney disorder types in children with kidney disease (0-17 years old) who are commercially insured, as of December 31, 2019. * CAKUT (congenital anomalies of the kidney and urinary tract): Approximately 83% * GN (glomerulonephritis): Approximately 10% * Cystic: Approximately 5% * Diabetes-related: Approximately 1% * CKD NOS (chronic kidney disease not otherwise specified): Approximately 10% * Other: Approximately 2% 4. Summary of Key Epidemiological Findings * Primary Finding 1: Congenital anomalies of the kidney and urinary tract (CAKUT) are by far the most common type of kidney disorder in

Review source

Epidemiology evidence 2: Trends in the Mortality Rate of Major Kidney Diseases — China, 2014–2021 Trends in the Mortality Rate of Major Kidney Diseases— China, 2014–2021

Luo PF, Yu H, Han RQ, Zhou JY, Wu M. Mortality and years of life lost caused by major kidney diseases in Jiangsu province, 2010-2018. Dis Surveill 2020;35(6):489 − 94. https://doi-org.sutd.idm.oclc.org/10.3784/j.issn.1003- 9961.2020.06.008. 1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020;395 (10225):709 − 33. https://doi-org.sutd.idm.oclc.org/10.1016/S0140-6736(20)30045-3. 2. IHME. Global burden of disease study 2019 (GBD2019) data resources. https://vizhub.healthdata.org/gbd-results/.[2024-3-23]. 3. Li Y, Ning YC, Shen B, Shi YQ, Song NN, Fang Y, et al. Temporal trends in prevalence and mortality for chronic kidney disease in China from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019. Clin Kidney J 2023;16(2):312 − 21. https://doi-org.sutd.idm.oclc.org/10.1093/ckj/ sfac218. 4. Safiri S, Kolahi AA, Mansournia MA, Almasi-Hashiani A, Ashrafi- Asgarabad A, Sullman MJM, et al. The burden of kidney cancer and its attributable risk factors in 195 countries and territories, 1990-2017. Sci Rep 2020;10(1):13862. https://doi-org.sutd.idm.oclc.org/10.1038/s41598-020-70840-2. 5. Safiri S, Hassanzadeh K, Ghaffari Jolfayi A, Mousavi SE, Motlagh Asghari K, Nejadghaderi SA, et al. Kidney cancer in the Middle East and North Africa region: a 30-year analysis (1990-2019). Sci Rep 6.

Review source

Epidemiology evidence 3: 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

• The longitudinal analysis of the RaDar cohort included 27 285 participants with 28 rare kid­ ney diseases and median follow-up of 9.6 years.22 Autosomal dominant polycystic kidney disease and immunoglobulin A nephropathy were the most fre­ quent diagnoses, with Bartter syndrome being the least frequent. The median age at diagnosis for the entire population was 40 years (IQR, 23.7–57.1 years), with variations across different groups of rare diseases. The highest cumulative kidney failure events were seen in certain diseases (eg, cystinosis and antiglomerular basement membrane disease, both at >80%). High kidney failure cumulative events were also observed in less rare diagnoses (30% in X-linked Alport, 16% in thin basement membrane, and 60% in immunoglobulin A nephrop­ athy). The median age at kidney failure also ranged from 15.4 years (IQR, 11.6–19.9 years) for patients with cystinosis to 65 years in patients with diseases such as vasculitis, HNF1B mutations, thin basement membrane nephropathy, monoclonal gammopathy of renal significance, and membranous nephropathy. Social Drivers of CKDs/Equitable Health • According to NHANES 2017 to 2020, the preva­ lence of CKD was 20.4% for adults with less than a high school education, 16.1% for those with a high school degree or equivalent, and 12.0% for those with some college or more.1 • In the CKiD study, Black children with CKD were more likely than White children to have public insur­ ance (71% versus 38%), lower household income (62% versus 25% for annual household income ≤$30 000), and greater food insecurity (defined as rece

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Multicystic Dysplastic Kidney, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Multicystic Dysplastic Kidney thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: NCC

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules (PubMed:18270262, PubMed:21613606, PubMed:22009145, PubMed:36351028, PubMed:36792826). Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). May act either independently of IL18R1, or in a complex with IL18R1 (By similarity).

The mechanism anchor is SLC12A3, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 62 registered studies.

• NCT07624019 — Renal SWE as a Predictor After Pediatric Pyeloplasty for UPJO (UPJO-SWE); Recruiting; Not Applicable; sponsor Beni-Suef University; enrollment 84.
• NCT07596810 — Ketamine Added to Quadratus Lumborum Block for Pain Relief After Infant Pyeloplasty (KETA-QLB); Completed; Phase 4; sponsor Alexandria University; enrollment 40.
• ChiCTR2500109358 — Efficacy and Safety of Laparoscopic Pyeloplasty Combined with Modified Percutaneous Nephrolithotomy for the Treatment of Ureteropelvic Junction Obstruction with Concurrent Lower Calyceal Stones; Completed; Not Applicable; sponsor Xijing Hospital; enrollment 35.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate SLC12A3 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Multicystic Dysplastic Kidney merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Multicystic Dysplastic Kidney is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.